Bioinformatic analysis of endothelial progenitor cells exposed to folic acid in type 1 diabetes mellitus

D.N. Fang¹, X.D. He¹, X.H. Li¹, H. Jia¹, P.Y. Li², Q. Lu³, Z. Quan⁴ and Q.L. Wang⁷

¹Department of Gastroenterology, Shanghai Eighth People’s Hospital, Shanghai, China
²Department of Endocrinology the First Affiliated Hospital of Xinjiang Medical University, Xinjiang, China
³Department of Emergency Medicine, The Fourth Affiliated Hospital of China Medical University, Shenyang, China
⁴Department of Anatomy and Embryology, Shanghai Medical College of Fudan University, Shanghai, China
⁵Department of Obstetrics and Gynecology, Central Hospital, Fengxian District, Shanghai, China
⁶Department of Neurosurgery, Central Hospital, Fengxian District, Shanghai, China
⁷Department of Histology and Embryology, School of Basic Medical, Shanghai University of Traditional Chinese Medicine, Shanghai, China

Corresponding authors: Z. Quan / Q.L. Wang
E-mail: zhequanzq@hotmail.com / wlei810@gmail.com

Received April 31, 2013
Accepted October 4, 2013
Published January 3, 2014
DOI http://dx.doi.org/10.4238/2014.January.3.1

ABSTRACT. We investigated the effects of type 1 diabetes mellitus (T1DM) on endothelial progenitor cells (EPCs) at the molecular level and assessed the therapeutic potential of folic acid (FA) in DM. We downloaded the gene expression profile of the EPCs from T1DM patients before and after treatment with FA and from healthy controls. We identified the
differentially expressed genes (DEGs) in the EPCs from T1DM patients before and after a four-week period of FA treatment and compared them with those obtained from the healthy subjects by using limma package in R language. Then, functional annotation of the DEGs was performed using the online tool Database for Annotation, Visualization and Integrated Discovery (DAVID) based on the Kyoto Encyclopedia of Genes and Genomes database. The expression of 696 genes was altered in the EPCs from T1DM patients compared to those from the healthy controls. These genes were mainly involved in the pathways associated with immune response. FA can normalize majority of the altered gene expression profiles of EPCs from T1DM patients to resemble those of healthy subjects, albeit with some side effects. FA can be a potential therapeutic agent for the treatment of T1DM. However, focused efforts are required to ensure that the dose of FA falls within the permissible pharmacological range.

Key words: Type 1 diabetes mellitus; Folic acid; Immune response; Endothelial progenitor cells; Differentially expressed genes

INTRODUCTION

Type 1 diabetes mellitus (T1DM) is a form of diabetes mellitus that results from autoimmunity-induced destruction of insulin-producing beta cells of the pancreas (Atkinson and Maclaren, 1994; Schranz and Lernmark, 1998). It generally develops in the young, and accounts for approximately 5-10% of the diabetic population worldwide (Daneman, 2006). Individuals with diabetes mellitus are at high risk for both microvascular and macrovascular complications, and are associated with endothelial dysfunction, premature atherosclerosis, and reduced ability for angiogenesis in ischemic conditions (Williams et al., 1996; Sheetz and King, 2002; Nathan et al., 2003).

T1DM is a multifactorial process, and both genetic and environmental factors are involved in its initiation and progression. Many studies have shown that beta cell autoantigens and immunocytes such as macrophages, dendritic cells, and T cells and their secretory products were involved in the pathogenesis of T1DM (Voorbij et al., 1989; Christianson et al., 1993; Jansen et al., 1994; Yoon and Jun, 2005). In addition, recent studies suggested that patients with T1DM have decreased numbers of endothelial progenitor cells (EPCs) and impaired functional capacity (Hill et al., 2003; Loomans et al., 2004; Tamarat et al., 2004). Folic acid (FA) is form of the water-soluble vitamin B9, which plays an important role in aiding rapid cell division and growth. Studies have shown that FA supplementation restores endothelial function in patients with coronary artery disease, hypercholesterolemia, and types 1 and 2 DM (Verhaar et al., 1998; Wilmink et al., 2000; Doshi et al., 2001; Pena et al., 2004; Title et al., 2006). However, the therapeutic potential of FA in DM remains to be fully elucidated. In addition, the effects of T1DM on EPCs are not well characterized at the molecular level.

In this study, we downloaded the gene expression profile of EPCs in T1DM patients and compared it to that of healthy controls, and then used bioinformatic-based methods to identify differential expression and its function. Furthermore, we analyzed the gene expression profiles of EPCs in FA-treated T1DM patients and compared it to that of healthy controls.
in order to investigate the outcome of FA treatment in T1DM patients. We believe that our study will improve the understanding of the molecular mechanism of T1DM and shed some light on the therapeutic studies for T1DM.

**MATERIAL AND METHODS**

**Microarray data**

Transcriptional profile of GSE17635 was downloaded from Gene Expression Omnibus, which is based on the platform of Sentrix HumanRef-8 Expression Beadchip. This dataset was deposited by Oostrom (van Oostrom et al., 2009). EPC samples were collected from 20 patients with T1DM and 20 age- and gender-matched healthy control subjects. Patients with T1DM were then treated with FA (5 mg/day) for 4 weeks, after which EPC samples were collected again. A total of 32 chips were available for further analysis, including 11 chips of EPC samples from T1DM patients, 10 chips of EPC samples from T1DM patients after FA treatment, and 11 chips of EPC samples from healthy controls.

**Pathway data**

Kyoto Encyclopedia of Genes and Genomes (KEGG) is a collection of online databases dealing with genomes, enzymatic pathways, and biological chemicals (Kanehisa, 2002). The PATHWAY database records networks of molecular interactions in the cells, and variants of them specific to particular organisms (http://www.genome.jp/kegg/). A total of 130 pathways, involving 2287 genes, were collected from KEGG.

**Data preprocessing and differential expression analysis**

We first converted the probe-level data in the CEL files into expression measures. For each sample, the expression values of all probes for a given gene were reduced to a single value by using the average expression value. We then imputed the missing data (Troyanskaya et al., 2001) and performed quartile data normalization (Fujita et al., 2006). The limma package (Diboun et al., 2006) in R Development Core Team (2011) was used to identify differentially expressed genes (DEGs) in the EPCs from patients with DM1 before and after FA treatment and to compare them with those of healthy controls. To circumvent the multi-test problem that might lead to an increase in the false-positive results, the BH method (Benjamini and Hochberg, 1995) was used to adjust the raw P values into false discovery rate (FDR). An FDR of < 0.05 was used as the cut-off criterion.

**Pathway enrichment analysis**

The Database for Annotation, Visualization and Integrated Discovery (DAVID) provides a comprehensive set of functional annotation tools for investigators to understand the biological meaning underlying the large list of genes (Huang da et al., 2009). For functional annotation of the DEGs, we identified the overrepresented KEGG categories in pathways. A P value of < 0.05 was used as the cut-off criterion.
RESULTS

Identification of DEGs in the EPCs from patients with T1DM before and after FA treatment

For the dataset GSE17635, a total of 719 DEGs were identified at an FDR of 0.05, including 696 DEGs between T1DM patients and healthy controls, and 23 DEGs between T1DM patients after FA treatment and healthy controls. The number of DEGs in T1DM patients greatly decreased after treatment with FA. Thus, FA treatment can normalize gene expression to healthy control levels. The results of differential gene expression analysis are shown in Figure 1, with the Venn diagram depicting the distribution of 719 DEGs. A total of 696 genes were differentially expressed in T1DM patients compared to healthy controls, and only 23 genes were differentially expressed in T1DM patients after FA treatment compared to the healthy controls. The intersect shows that three genes (HCLS1, CECR1, and TNSRSF21) with differential expression between T1DM and healthy controls cannot be modulated by FA treatment. The remaining 20 genes may associate with side effects of FA treatment. To facilitate further analysis, we named the DEGs between T1DM patients and healthy controls (693 genes) as gene set 1, and the other two groups of DEGs were named as gene set 2 (20 genes) and gene set 3 (3 genes).

![Figure 1](image_url)

**Figure 1.** A Venn diagram depicting differential gene expression. The blue region represents DEGs in T1DM patients compared to healthy controls. The orange region represents DEGs in T1DM patients after FA treatment compared to healthy controls.

Functional annotation of DEGs

To investigate the effect of T1DM on EPC gene expression at the functional level, the DEGs in the EPCs of patients with T1DM before and after FA treatment compared to those of the healthy controls were input into the DAVID for pathway enrichment analysis. At a P value of 0.05, the DEGs in gene set 1 were enriched in 3 pathways (Table 1). The most significant enrichment was the pathway of graft-versus-host disease with a P value of 0.15714. The other significant pathways included arachidonic acid metabolism (P value = 0.019411) and antigen processing and presentation (P value = 0.03898). In fact, all significant pathways were related to immune response. The other two groups of DEGs were not enriched in any pathways.
Functional interaction network analysis of DEGs in gene sets 2 and 3

The DEGs in gene set 1 were successfully mapped to 3 KEGG pathways, while the other two groups of DEGs were not enriched in any pathways. To further analyze these DEGs, we mapped them to the Search Tool for the Retrieval of Interacting Genes (STRING) database (Szklarczyk et al., 2011) to predict the interacting genes. A total of 2630 and 487 interacting relationships, which involved 218 and 164 genes, were identified in gene sets 2 and 3, respectively. By integrating these relationships, we constructed two interaction networks (Figures 2 and 3). Functional annotation showed that the DEGs in set 2 and their interacting genes were enriched in 11 pathways, including phosphatidylinositol signaling system, glycosphingolipid biosynthesis, and neuroactive ligand-receptor interaction (Table 2). The DEGs in set 3 and their interacting genes were enriched in 3 pathways: viral myocarditis, allograft rejection, and graft-versus-host disease (Table 3).

Table 1. The enriched pathways of differentially expressed genes between T1DM patients and healthy controls.

<table>
<thead>
<tr>
<th>KEGG-ID</th>
<th>Term</th>
<th>P value</th>
<th>Genes</th>
</tr>
</thead>
<tbody>
<tr>
<td>hsa05332</td>
<td>Graft-versus-host disease</td>
<td>0.015714</td>
<td>HLA-DPA1, HLA-B, HLA-DPB1, KIR2DL2, HLA-G, KLRC1</td>
</tr>
<tr>
<td>hsa00590</td>
<td>Arachidonic acid metabolism</td>
<td>0.019411</td>
<td>CYP2U1, GGT5, GGT6, CYP4F3, CYP4F2, PLA2G3, PLA2G5</td>
</tr>
<tr>
<td>hsa04612</td>
<td>Antigen processing and presentation</td>
<td>0.03898</td>
<td>RFX5, CREB1, HLA-DPA1, HLA-B, HLA-DPB1, KIR2DL2, HLA-G, KLRC1</td>
</tr>
</tbody>
</table>

Figure 2. Interaction network constructed in gene set 2. The red nodes represent the differentially expressed genes and the other nodes represent their interacting genes in STRING.
Figure 3. Interaction network constructed in gene set 3. The red nodes represent the differentially expressed genes and the other nodes represent their interacting genes in STRING.

Table 2. Enriched pathways of differentially expressed genes in gene set 2 and their interacting genes.

<table>
<thead>
<tr>
<th>KEGG-ID</th>
<th>Term</th>
<th>P</th>
<th>FDR</th>
</tr>
</thead>
<tbody>
<tr>
<td>hsa04070</td>
<td>Phosphatidylinositol signaling system</td>
<td>1.51E-17</td>
<td>1.68E-14</td>
</tr>
<tr>
<td>hsa00601</td>
<td>Glycosphingolipid biosynthesis</td>
<td>4.50E-17</td>
<td>5.00E-14</td>
</tr>
<tr>
<td>hsa04080</td>
<td>Neuroactive ligand-receptor interaction</td>
<td>1.84E-16</td>
<td>2.44E-13</td>
</tr>
<tr>
<td>hsa00562</td>
<td>Inositol phosphate metabolism</td>
<td>2.64E-13</td>
<td>2.93E-10</td>
</tr>
<tr>
<td>hsa00240</td>
<td>Pyrimidine metabolism</td>
<td>5.95E-10</td>
<td>6.61E-07</td>
</tr>
<tr>
<td>hsa04020</td>
<td>Calcium signaling pathway</td>
<td>2.44E-08</td>
<td>2.70E-05</td>
</tr>
<tr>
<td>hsa00983</td>
<td>Drug metabolism</td>
<td>6.32E-07</td>
<td>7.01E-04</td>
</tr>
<tr>
<td>hsa04666</td>
<td>Fc gamma R-mediated phagocytosis</td>
<td>1.38E-06</td>
<td>0.001529</td>
</tr>
<tr>
<td>hsa04664</td>
<td>Fc epsilon R1 signaling pathway</td>
<td>5.10E-06</td>
<td>0.005662</td>
</tr>
<tr>
<td>hsa00760</td>
<td>Nicotinate and nicotinamide metabolism</td>
<td>6.41E-06</td>
<td>0.007118</td>
</tr>
<tr>
<td>hsa04722</td>
<td>Neurotrophin signaling pathway</td>
<td>7.24E-06</td>
<td>0.008041</td>
</tr>
</tbody>
</table>
DISCUSSION

In this study, we used bioinformatic methods to investigate the molecular mechanism underlying T1DM and the effects of FA on the transcriptome of EPCs from T1DM patients. The results showed that the expression of 696 genes was altered in the EPCs from T1DM patients compared to that in the EPCs from healthy controls. These genes were mainly involved in pathways associated with immune response, such as graft-versus-host disease, arachidonic acid metabolism, and antigen processing and presentation. Furthermore, we showed that FA could normalize a majority of altered gene expression profiles of EPCs from T1DM patients to resemble those of EPCs from healthy subjects, albeit with some side effects.

T1DM is related to reduced vascular repair, as indicated by impaired wound healing and reduced collateral formation in ischemia (Abaci et al., 1999). Previous studies have shown that EPC is an important regulator of these processes and that adverse metabolic stress factors in T1DM are associated with reduced EPC numbers and angiogenesis (Asahara et al., 1999; Loomans et al., 2004; Tamarat et al., 2004). To improve the impaired numerical and functional capacity of EPCs, it is necessary to identify the genes affected by T1DM. We observed an effect of T1DM on the members of the major histocompatibility complex family (HLA-DPA1, HLA-B, HLA-DPB1, and HLA-G) and killer cell immunoglobulin-like receptors (KIR2DL2 and KLRC1) involved in the pathway of graft-versus-host disease. The HLA-DPA1 and DPB1 genes are the third set of classical HLA class II loci that code for the DP antigen and are associated with lower immunostimulatory capacity and level of expression (Pawelec and Buhring, 1990). Recently, Varney et al. (2010) suggested these two genes contributed to the risk associated with T1DM. The major histocompatibility complex class I genes (HLA-B and HLA-G) were also found to contribute to the etiology of T1DM (Abediankenari et al., 2007; Nejentsev et al., 2007). Killer cell immunoglobulin-like receptors on chromosome 19q13.4 regulate the function of not only human natural killer cells but also T cells. Ramos-Lopez suggested a potential role of the KIR2DL2-rs 2756923 polymorphism in T1DM in the German and Belgian populations (Ramos-Lopez et al., 2009).

To further explore the molecular mechanism of T1DM, we analyzed the most significant dysfunctional pathway of graft-versus-host disease in KEGG (Figure 4). Graft-versus-host disease is a lethal complication of allogeneic hematopoietic stem cell transplantation, wherein the immunocompetent donor T cells attack the genetically disparate host cells. The pathophysiology of graft-versus-host disease can be summarized in a three-step process, and nitric oxide (NO) is produced by activated macrophages during step 2. Hyperglycemia increases the production of superoxide (O$_2^-$) and reduces the bioavailability of NO resulting in the development of endothelial dysfunction in DM patients (Dimmeler et al., 2002; Creager et al., 2003). Therefore, we suggested that the production of NO during step 2 of the graft-versus-host disease plays a role in EPC dysfunction in patients with T1DM.
Previous studies have shown that FA exerts protective anti-oxidant effects and improves endothelial function in patients with cardiovascular diseases (Doshi et al., 2001; Pena et al., 2004; Antoniades et al., 2006). In this study, we assessed the effect of FA treatment on T1DM by analyzing the gene expression profile of EPCs from T1DM patients treated with FA and comparing it to that from healthy controls. Indeed, FA normalized a majority of changes in gene expression induced by T1DM (99.6%), suggesting the therapeutic potential of FA in the treatment of T1DM. However, we also found 20 DEGs between T1DM patients and healthy controls. These differential expressions were induced by FA treatment, and they might be associated with the side effects of FA treatment. Functional interaction network analysis showed that FA treatment might cause dysregulation of metabolism, such as in case of inositol phosphate metabolism and pyrimidine metabolism. Therefore, we suggested that focused efforts should be invested to ensure that the dose of FA falls within the pharmacological range, especially in case of diabetic pregnancy (Capel and Corcoy, 2007). This result is inconsistent with that of the original study, which suggested that the gene expression profiles of EPCs from healthy controls and T1DM patients after FA treatment were very similar and that pairwise comparison showed no DEGs at an FDR of 0.05 (van Oostrom et al., 2009). We hypothesized that these differences may be due to the different method used for the analysis of microarray data.

In conclusion, our study employed bioinformatics methods to elucidate the molecular mechanism underlying T1DM and the effects of FA treatment on the transcriptome of EPCs from patients with T1DM. We observed a remarkable effect of FA treatment with respect to normalization of the altered gene expression induced by T1DM, and a new differential gene expression pattern that may be associated with the potential side effects of FA treatment.

**REFERENCES**


